Ani Pharmaceuticals (ANIP) Revenue Growth (1y) (2011 - 2026)
Ani Pharmaceuticals (ANIP) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -0.81% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -0.24% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 0.07% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -1.92% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 4.88% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 39.49% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 10.23% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 25.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.87% |
| Mar 31, 2026 | 20.46% |
| Dec 31, 2025 | 29.64% |
| Sep 30, 2025 | 53.58% |
| Jun 30, 2025 | 53.12% |
| Mar 31, 2025 | 43.43% |
| Dec 31, 2024 | 44.75% |
| Sep 30, 2024 | 12.52% |
| Jun 30, 2024 | 18.44% |
| Mar 31, 2024 | 28.70% |
| Dec 31, 2023 | 39.71% |
| Sep 30, 2023 | 57.27% |
| Jun 30, 2023 | 57.81% |
| Mar 31, 2023 | 65.62% |
| Dec 31, 2022 | 54.66% |
| Sep 30, 2022 | 61.01% |
| Jun 30, 2022 | 51.89% |
| Mar 31, 2022 | 475.69% |
| Dec 31, 2021 | 6.42% |
| Sep 30, 2021 | -1.73% |